MariTide

News

Amgen's big reveal of obesity data falls a little flat

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations

News

Amgen plays down safety concern with obesity candidate

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t

News

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks